文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

台湾北部某三级医院2017-2019年接受联合抗逆转录病毒治疗的低水平病毒血症HIV感染者耐药突变流行率

Prevalence of drug resistance mutations in HIV-infected individuals with low-level viraemia under combination antiretroviral therapy: an observational study in a tertiary hospital in Northern Taiwan, 2017-19.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

约半数LLV病例存在依从性欠佳或治疗中断,68.8%(11/16)在LLV时未显示对其ART方案的耐药。

要点

  • LLV病例NRTI耐药率低于治疗失败组,提示耐药谱不同。
  • 约半数LLV病例存在依从性问题,多数未显示对当前方案耐药。

核心结论

  • LLV病例的HIV耐药突变谱与未治疗和治疗失败病例显著不同。
  • LLV病例中NNRTI耐药突变率高于未治疗组,NRTI耐药突变率低于治疗失败组。
  • 需巩固ART依从性并早期探索潜在耐药。

研究设计与样本

  • 前瞻性观察性研究,2017-2019年于台湾北部一家三级医院开展。
  • 采用HIV-DNA作为HIV-RNA的替代进行基因型检测,结合深度测序。

主要发现

  • LLV组NNRTI耐药突变率为69%,未治疗组为20%(P<0.001)。
  • LLV组NRTI耐药突变率为25%,治疗失败组为61%(P<0.001)。
  • 约半数LLV病例存在依从性欠佳或治疗中断。
  • 68.8%(11/16)的LLV病例在LLV时未显示对其ART方案的耐药。

临床怎么用

  • 对LLV病例应评估依从性并考虑早期耐药检测。
  • LLV耐药谱不同于治疗失败,需个体化评估耐药风险。

局限性

  • 样本量较小,LLV病例仅16例。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Effective ART is crucial for combating the HIV pandemic. Clinically, plasma viral load monitoring to achieve virological suppression is the guide for an optimal ART. The presence of low-level viraemia (LLV) below the definition level of virological failure is a risk factor for ART failure. However, there is no treatment consensus over LLV yet, mainly due to the limitation of standard HIV-RNA genotyping and the resultant insufficient understanding of LLV characteristics. OBJECTIVES: To better profile drug resistance mutations (DRMs) and the associated factors in cases experiencing LLV. METHODS: A prospective observational study was conducted from 2017 to 2019. HIV-DNA was used as an alternative to HIV-RNA for HIV genotyping coupled with deep sequencing for ART-naive and ART-failure cases, as well as those with LLV. RESULTS: Eighty-one ART-naive, 18 ART-failure and 16 LLV cases received HIV genotyping in the study. Three-quarters (12/16) of cases experiencing LLV harboured DRMs. Cases with LLV had higher prevalence of DRMs to NNRTIs than the ART-naive group (69% versus 20%, P < 0.001), but lower DRM prevalence to NRTIs than the ART-failure group (25% versus 61%, P < 0.001). Approximately half of the LLV cases had issues of suboptimal ART compliance/ART interruption, and 68.8% (11/16) did not display drug resistance to their ART at the time of LLV. CONCLUSIONS: HIV DRM profiles in LLV cases were significantly different to those in ART-naive and ART-failure cases. Approaches to consolidate ART compliance and early exploration of potential ART resistance may be needed for cases experiencing LLV episodes.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Kao SW, Liu ZH, Wu TS, et al. Prevalence of drug resistance mutations in HIV-infected individuals with low-level viraemia under combination antiretroviral therapy: an observational study in a tertiary hospital in Northern Taiwan, 2017-19. J Antimicrob Chemother. 2021. PMID: 33331635. doi:10.1093/jac/dkaa510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。